Gene Therapy in CNS Disorder Market Forecast 2023 to 2033 | By Type, Indication, End-Users & Region

The global Gene Therapy in CNS Disorders Market size is expected to reach US$ 8.2 billion in 2023 and US$ 103.04 billion by 2033, with a compound annual growth rate (CAGR) of 30% between 2023 and 2033. The market for gene therapy in CNS diseases grew at a 19% CAGR from 2018 to 2022.

The rising prevalence of CNS disorders, particularly neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and multiple sclerosis, is a major driver of this expansion. The incidence of these illnesses is predicted to rise as the world population ages, resulting in a large healthcare burden and boosting demand for effective treatments.

For Details on Vendors and Their Offerings – Request A Sample Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16744

Furthermore, increased investment in gene therapy research and development is likely to accelerate the development of new CNS medicines. Regulatory bodies such as the FDA have established expedited procedures for gene therapy treatment approval and review, allowing for faster development and commercialization of these therapeutics.

Key Takeaways from the Market Study

• From 2018 to 2022, the Gene Therapy in CNS Disorder market grew at a 19% CAGR.
• The global Gene Therapy in CNS Disorder market is expected to grow at a 30% CAGR between 2023 and 2033.
• The market for Gene Therapy in CNS Disorders is expected to reach US$ 113.04 billion by 2033.
• According to FMI study, hospitals have the largest market share.
• It is anticipated that North America will account for 40% of the market for Gene Therapy in CNS Disorders.
• The market in East and South Asia is predicted to increase significantly throughout the projection period, accounting for 20% of the total. 

“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fuelling further clinical trials and research studies dedicated to discovering Gene Therapy in CNS Disorder.” says an FMI analyst

Last few days to get reports at discounted prices, offer expires soon!

Request Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-16744

Market Competition

Key players in the market include companies such as Voyager Therapeutics, Spark Therapeutics, Novartis AG, Bluebird bio, Inc., Biogen, Pfizer Inc., Rapa Therapeutics, BrainStorm Cell Therapeutics, Eli Lilly and Company, and UniQure Biopharma, along with healthcare providers and technology companies among other global players.

• In November 2022, A team of researchers at University College London (UCL) developed a novel gene therapy that offers promise in treating neurological and psychiatric disorders. The therapy targets overactive brain cells that are responsible for causing several brain diseases, including epilepsy, by reducing their excitability. By using DNA sequences that control gene expression, the therapy drives the production of molecules that prevent these overactive cells from firing, thereby curbing epileptic seizures. Notably, the technique selectively alters only overactive cells while sparing normally functioning cells.

In preclinical studies, the new treatment demonstrated a higher efficacy than previous gene therapies or anti-seizure drugs tested in the same model. The team observed an approximately 80% reduction in spontaneous seizures in epileptic mice treated with the therapy. Furthermore, the researchers believe that this gene therapy has the potential to treat other disorders where some brain cells are overactive, such as Parkinson’s disease.

More Insights Available

North America is projected to dominate the Gene Therapy market due to the presence of a well-established healthcare infrastructure, significant investment in gene therapy research and development, and favorable regulatory policies. The United States is expected to contribute the most significant share of the market due to its advanced healthcare system and high incidence of CNS disorders.

We Offer tailor-made Solutions to fit Your Requirements, Request Customization@ https://www.futuremarketinsights.com/customization-available/rep-gb-16744

Key Segments Profiled in the Gene Therapy in CNS Disorder Industry Survey

Indication:

• Alzheimer’s Disease
• Huntington’s Disease
• Parkinson’s Disease
• Batten Disease

Type:

• Ex Vivo
• In Vivo

End User:

• Hospitals
• Speciality Clinics

About Future Market Insights, Inc.

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs